Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma. Secondary Objective: To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard to: * Safety and tolerability * Dupilumab systemic exposure and anti-drug antibodies
Total duration per participant of approximately 43 weeks including a screening period (14-21 days), a randomized treatment period (24 weeks), and a post-treatment period (16 weeks).
Solution for injection, Subcutaneous injection
Solution for injection, Subcutaneous injection
Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Oral inhalation as needed
Oral inhalation as needed
Buenos Aires, Argentina
Buenos Aires, Argentina
Caba, Argentina
Caba, Argentina
Caba, Argentina
La Plata, Argentina
Rosario, Argentina
Rosario, Argentina
Rosario, Argentina
San Miguel de Tucumán, Argentina
Santa Fe, Argentina